Mechanism exploration and clinical verification of new integrated markers of capecitabine clinical effect

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037696

Enrollment

Unknown

Registered

2020-08-30

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Capecitabine:Nil

Capecitabine + Bevacizumab/ Cetuximab:Nil

Capecitabine + Oxaliplatin:Nil

Capecitabine + Oxaliplatin + Bevacizumab/Cetuximab:Nil

Capecitabine + radiotherapy:Nil

Irinotecan + capecitabine:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with age greater than (including) 18 years old; 2. Patients who were diagnosed as colon cancer by pathological biopsy (regardless of the stage of cancer); 3. Patients who received chemotherapy programs containing capecitabine (produced by Roche or Hengrui) after operation; 4. Patients who voluntarily signed informed consent to join the trial.

Exclusion criteria

Exclusion criteria: 1. Pregnant women and patients in lactation period; 2. The patients who are allergic to fluorouracil drugs or have serious metabolisms; 3. Patients with severe infection; 4. Patients with other cancers besides colorectal cancer within 5 years before surgery; 5. Patients who are considered unsuitable for the study.

Design outcomes

Primary

Measure	Time frame
Three-year disease-free survival;	—

Secondary

Measure	Time frame
Progression-free survival;	—

Countries

China

Contacts

Public ContactWei Hua

Shanghai Changzheng Hospital

shczjgb@163.com+86 13636491563

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026